Medical Ethics, Legal and Regulatory Issues 9 Flashcards

A COT is assisting in a clinical research study. A patient enrolled in the trial experiences a sudden significant decrease in visual acuity between scheduled visits and calls to report the symptom. The principal investigator (PI) is traveling internationally and unreachable. What is the most appropriate immediate action?

Answer: Follow the protocol's adverse event procedures, escalate to the co-investigator or covering physician, and ensure the patient receives timely evaluation

Clinical research protocols must include provisions for managing adverse events when the PI is unavailable. The correct action is to follow the study's adverse event procedures, which require escalation to a designated co-investigator or covering physician and prompt patient evaluation. Waiting until the next scheduled visit violates patient safety obligations and federal research regulations (45 CFR 46). Contacting the IRB first delays care — IRB reporting is required but not the first clinical step. Sending the patient to the ER without attempting protocol-designated backup is premature.

A long-term patient with bilateral advanced glaucoma and a best-corrected visual acuity of 20/200 in his better eye discloses he is a licensed commercial motor vehicle (CMV) operator. Your state has a mandatory physician reporting law for vision-impairing conditions that affect driving fitness. The patient explicitly refuses consent to report and threatens to leave the practice if reported. What is the ethically and legally correct course of action?

Answer: Fulfill the mandatory reporting obligation to the state DMV regardless of the patient's refusal, as mandatory reporting laws supersede individual consent requirements

Mandatory reporting laws for conditions affecting driving safety represent a legally established public health exception to patient confidentiality. When a state law mandates reporting of vision-impairing conditions to licensing authorities, the provider is legally obligated to report regardless of patient consent — this is not a HIPAA violation because mandatory legal reporting is an explicitly permitted disclosure under 45 CFR §164.512(a). A CMV operator with 20/200 VA in the better eye fails federal FMCSA vision standards (minimum 20/40 in better eye), creating serious third-party risk. Waiting for a second opinion or limiting reporting to post-accident events would expose both the practice and the public to foreseeable harm.

During a routine exam, a 16-year-old patient seen without a parent present confides to the COT that she has been purchasing and using unprescribed contact lenses ordered from a foreign website and has developed persistent eye pain. She begs the COT not to tell her parents. Under what circumstance would disclosure to her parents WITHOUT her consent be most clearly ethically and legally justified?

Answer: Disclosure is justified if the clinical findings indicate a condition (such as a corneal ulcer) that poses imminent risk of serious, irreversible harm requiring urgent parental consent for treatment

While minors have growing privacy rights, parental notification without assent is ethically justified — and often legally required — when there is imminent risk of serious irreversible harm and the minor lacks legal capacity to consent to necessary treatment. Corneal ulcer from contaminated or improperly fitted non-prescription contacts can progress to permanent vision loss within hours. In this scenario, the minor cannot consent to the corneal culture, antibiotic treatment, or possible surgical intervention that may be required, making parental involvement clinically necessary. This is distinct from routine confidential adolescent services (STI testing, contraception) where most states protect minor confidentiality. Court orders are not required in emergency situations involving minors.

A patient presents with a valid Durable Power of Attorney for Healthcare (DPOA-HC) designating her adult daughter as her healthcare proxy. The patient is alert and oriented, scores 30/30 on a brief cognitive screen, and clearly states she does NOT want dilation performed today due to transportation concerns. The daughter insists dilation is medically necessary and demands the technician proceed, citing the DPOA-HC document. What is the correct course of action?

Answer: Respect the patient's refusal; a healthcare proxy only has authority when the patient lacks decision-making capacity, and this patient clearly retains capacity

A Durable Power of Attorney for Healthcare activates only when the patient lacks decision-making capacity — it is not a general override of a capacitated patient's autonomy. This patient is alert, oriented, and cognitively intact, meaning she retains full legal and ethical authority over her own healthcare decisions. The daughter has no authority to override a capacitated patient's refusal regardless of the DPOA-HC document. Proceeding with dilation against a capacitated patient's explicit refusal constitutes battery. The correct action is to honor the patient's refusal, document it thoroughly, and educate both patient and family about the purpose of the DPOA-HC document.

A pharmaceutical company representative asks the practice manager if Dr. Smith performs a high volume of intravitreal injections, offering to share prescribing data they obtained from a data broker in exchange for scheduling a lunch presentation. A COT overhears the conversation. Which statement most accurately describes the legal and ethical issues involved?

Answer: While the data broker's sale may be technically legal under certain exemptions, accepting the data in exchange for pharmaceutical access could implicate anti-kickback statutes and the practice's ethics policy

This scenario involves two intersecting issues. First, aggregate prescribing data sold through pharmacy data pipelines has historically operated in a gray zone — the Supreme Court addressed related First Amendment issues in Sorrell v. IMS Health (2011). However, the exchange of this data as an implicit quid pro quo for pharmaceutical company access (scheduling a sales lunch) can implicate the Anti-Kickback Statute (AKS), which prohibits offering or receiving anything of value to induce or reward referrals or purchasing of items covered by federal health programs. 42 U.S.C. §1320a-7b(b). Filing an HHS complaint about the data broker is not the COT's role here, and the data is not necessarily a HIPAA violation at the broker level. The correct concern is the potential AKS exposure from the exchange arrangement.

A COT working in a multi-specialty clinic is asked by a nurse practitioner (NP) from an adjacent department — not the supervising ophthalmologist — to perform a visual field test on that NP's patient, who has neurological symptoms. The COT's state license authorizes visual field testing under 'appropriate supervision.' What is the primary regulatory concern?

Answer: The COT performing procedures under supervision of a provider outside their defined supervisory relationship likely violates scope-of-practice regulations and may expose the COT's license to disciplinary action

Most state laws governing ophthalmic allied health personnel specify that supervision must be provided by a licensed ophthalmologist or in some states an optometrist — not by any physician or NP. An NP, regardless of prescriptive authority, is generally not a legally designated supervisor for COT scope-of-practice purposes under ophthalmic technician licensing statutes. Performing a procedure under supervision of an unauthorized supervisor means the COT is effectively practicing without proper supervision, which is a licensure violation. This is separate from and more fundamental than the billing concern. The COT should decline and explain that the patient would need to be seen by the ophthalmologist to whom the COT is credentialed.